INFU logo

InfuSystem Holdings, Inc. Stock Price

NYSEAM:INFU Community·US$243.6m Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 18 Fair Values set on narratives written by author

INFU Share Price Performance

US$12.19
2.59 (26.98%)
US$13.75
Fair Value
US$12.19
2.59 (26.98%)
11.3% undervalued intrinsic discount
US$13.75
Fair Value
Price US$12.19
AnalystConsensusTarget US$13.75
AnalystLowTarget US$12.00
AnalystHighTarget US$20.00

INFU Community Narratives

·
Fair Value US$13.75 11.3% undervalued intrinsic discount

Process Automation And Partnerships Will Expand Home Healthcare Services

0users have liked this narrative
0users have commented on this narrative
7users have followed this narrative
·
Fair Value US$15 18.7% undervalued intrinsic discount

ERP And Wound Care Risks Will Pressure Results Before Longer Term Potential Emerges

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
·
Fair Value US$20 39.1% undervalued intrinsic discount

Wound Care Momentum And ERP Efficiencies Will Reshape Long Term Earnings Power

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
US$20
39.1% undervalued intrinsic discount
Revenue
6.21% p.a.
Profit Margin
9.96%
Future PE
25.86x
Price in 2029
US$23.96
US$13.75
11.3% undervalued intrinsic discount
Revenue
8.17% p.a.
Profit Margin
6.98%
Future PE
24.38x
Price in 2028
US$16.64

Trending Discussion

No trending discussion available.

Updated Narratives

INFU logo

INFU: Compression Driven Growth Will Support Oncology Momentum Into 2027

Fair Value: US$15 18.7% undervalued intrinsic discount
0 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
INFU logo

INFU: Compression And Oncology Momentum Will Drive Profitable Upside Potential

Fair Value: US$20 39.1% undervalued intrinsic discount
1 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
INFU logo

Process Automation And Partnerships Will Expand Home Healthcare Services

Fair Value: US$13.75 11.3% undervalued intrinsic discount
7 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Flawless balance sheet with solid track record.

1 Risk
4 Rewards

InfuSystem Holdings, Inc. Key Details

US$143.3m

Revenue

US$61.0m

Cost of Revenue

US$82.4m

Gross Profit

US$73.8m

Other Expenses

US$8.5m

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
0.43
57.45%
5.96%
34.5%
View Full Analysis

About INFU

Founded
2005
Employees
467
CEO
Carrie Lachance
WebsiteView website
www.infusystem.com

InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps and related products and services in the United States and Canada. It operates through two segments: Patient Services and Device Solutions. The company supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states. It also sells and rents new and pre-owned pole-mounted and ambulatory infusion pumps, and other durable medical equipment; sells treatment-related consumables; and provides biomedical recertification, maintenance, and repair services for oncology practices, as well as other healthcare site settings comprising hospitals, home care and home infusion providers, skilled nursing and acute care facilities, pain centers, and others. In addition, the company offers local and field-based customer support, as well as operates pump service and repair centers. The company was incorporated in 2005 and is headquartered in Rochester Hills, Michigan.

Recent INFU News & Updates

Narrative Update Aug 05

INFU: Compression And Oncology Momentum Will Drive Profitable Upside Potential

Analysts have lifted their price target on InfuSystem Holdings to $20 from $12, citing a profitable growth thesis supported by recent results, expectations for compression driven growth into 2027, a potential rebound in equipment sales in the second half of 2026, and continued oncology momentum. What’s in the News for InfuSystem Holdings InfuSystem Holdings has been added to multiple Russell indexes, including the Russell 2000 Index, Russell 2500 Index, Russell 3000 Index and related growth and completeness benchmarks, which can affect index fund ownership and trading activity.

Recent updates

No updates